UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Metastatic renal carcinoma comprehensive prognostic system

British journal of cancer, 2003-02, Vol.88 (3), p.348-353

2003

Volltextzugriff (PDF)

A nine-gene signature predicting clinical outcome in cutaneous melanoma

Journal of cancer research and clinical oncology, 2013-02, Vol.139 (2), p.249-258

2013

Volltextzugriff (PDF)

Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

Journal of clinical oncology, 2004-04, Vol.22 (7), p.1188-1194

2004

Volltextzugriff (PDF)

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)

Journal of cancer research and clinical oncology, 2020-10, Vol.146 (10), p.2681-2691

2020

Volltextzugriff (PDF)

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

British journal of cancer, 2005-03, Vol.92 (5), p.843-846

2005

Volltextzugriff (PDF)

CXCR4/CXCL12 expression and signalling in kidney cancer

British journal of cancer, 2002-04, Vol.86 (8), p.1250-1256

2002

Volltextzugriff (PDF)

2049 AIO-KRK-0109: A randomized phase II trial of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as 1st-line treatment in RAS-wild-type metastatic colorectal cancer (mCRC)

European journal of cancer (1990), 2015-09, Vol.51, p.S344-S345

2015

Volltextzugriff (PDF)

An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma

British journal of cancer, 2006-06, Vol.94 (12), p.1785-1788

2006

Volltextzugriff (PDF)

IL-2 in combination with IFN-α and 5-FU versus tamoxifen in metastatic renal cell carcinoma : long-term results of a controlled randomized clinical trial

British journal of cancer, 2001-10, Vol.85 (8), p.1130-1136

2001

Volltextzugriff (PDF)

Résultats prometteurs de la triple association interféron α, interleukine 2 et 5 fluorouracile dans le traitement du cancer du rein métastasé

Pathologie et biologie, 1994, Vol.42 (1)

ATZPODIEN, J

1994

Volltextzugriff (PDF)

Combination chemotherapy with or without s.c. IL-2 and IFN-α: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)

British journal of cancer, 2002-01, Vol.86 (2), p.179-184

2002

Volltextzugriff (PDF)

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients

British journal of cancer, 2007-11, Vol.97 (10), p.1329-1332

2007

Volltextzugriff (PDF)

Rapid deterioration in quality of life during interleukin-2- and α-interferon-based home therapy of renal cell carcinoma is associated with a good outcome

British journal of cancer, 2003-07, Vol.89 (1), p.50-54

2003

Volltextzugriff (PDF)

Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

British journal of cancer, 2006-08, Vol.95 (4), p.463-469

2006

Volltextzugriff (PDF)

Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma

Critical reviews in oncology/hematology, 2005-09, Vol.55 (3), p.193-199

2005

Volltextzugriff (PDF)

Interleukin-2/interferon- alpha 2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

British journal of cancer, 2006-08, Vol.95 (4), p.463-469

2006

Volltextzugriff (PDF)

Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma

British journal of cancer, 1998-07, Vol.78 (1), p.40-45

1998

Volltextzugriff (PDF)

Chemoimmuntherapie des metastasierten Nierenzellkarzinoms

Der Onkologe, 2004-09, Vol.10 (9), p.934-940

2004

Volltextzugriff (PDF)

Peripheral Blood Tyrosinase Messenger RNA Detection and Survival in Malignant Melanoma

JNCI : Journal of the National Cancer Institute, 1996-05, Vol.88 (9), p.590-594

1996

Volltextzugriff (PDF)

Elevated serum levels of S100 and survival in metastatic malignant melanoma

British journal of cancer, 1997-05, Vol.75 (9), p.1373-1376

1997

Volltextzugriff (PDF)

Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma

British journal of cancer, 1999-03, Vol.79 (7-8), p.1182-1184

1999

Volltextzugriff (PDF)

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas : results of a phase-II study of the German low-grade lymphoma study group

Annals of hematology, 2000-09, Vol.79 (9), p.493-500

2000

Volltextzugriff (PDF)

Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma

British journal of cancer, 1998-07, Vol.78 (1), p.40-45

1998

Volltextzugriff (PDF)

Capecitabine in the treatment of metastatic renal cell carcinoma

British journal of cancer, 2000-09, Vol.83 (5), p.583-587

2000

Volltextzugriff (PDF)

Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies

The Lancet (British edition), 1990-06, Vol.335 (8704), p.1509-1512

1990

Volltextzugriff (PDF)

1 – 25 von 246

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(211)
Mit Volltextzugriff
(165)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(170)
Life Sciences & Biomedicine
(142)
Science & Technology
(142)
Biological And Medical Sciences
(103)
Medical Sciences
(96)
Male
(91)
Oncology
(91)
Middle Aged
(86)
Female
(84)
Adult
(73)
Aged
(72)
Immunotherapy
(51)
Pharmacology. Drug Treatments
(50)
Antineoplastic Agents
(47)
Interleukin-2 - Administration & Dosage
(40)
Interleukin-2 - Therapeutic Use
(34)
Carcinoma, Renal Cell - Therapy
(33)
Kidney Neoplasms - Therapy
(32)
Prognosis
(28)
Kidney Neoplasms - Pathology
(27)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Metastatic renal carcinoma comprehensive prognostic system

A nine-gene signature predicting clinical outcome in cutaneous melanoma

Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

CXCR4/CXCL12 expression and signalling in kidney cancer

2049 AIO-KRK-0109: A randomized phase II trial of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as 1st-line treatment in RAS-wild-type metastatic colorectal cancer (mCRC)

An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma

IL-2 in combination with IFN-α and 5-FU versus tamoxifen in metastatic renal cell carcinoma : long-term results of a controlled randomized clinical trial

Résultats prometteurs de la triple association interféron α, interleukine 2 et 5 fluorouracile dans le traitement du cancer du rein métastasé

Combination chemotherapy with or without s.c. IL-2 and IFN-α: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients

Rapid deterioration in quality of life during interleukin-2- and α-interferon-based home therapy of renal cell carcinoma is associated with a good outcome

Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma

Interleukin-2/interferon- alpha 2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma

Chemoimmuntherapie des metastasierten Nierenzellkarzinoms

Peripheral Blood Tyrosinase Messenger RNA Detection and Survival in Malignant Melanoma

Elevated serum levels of S100 and survival in metastatic malignant melanoma

Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas : results of a phase-II study of the German low-grade lymphoma study group

Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma

Capecitabine in the treatment of metastatic renal cell carcinoma

Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies

Suchergebnisse filtern